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Metabolic acidosis often accompanies low glomerular
filtration rate and induces secretion of endothelin, which in
turn might mediate kidney injury. Here we tested whether
treatment of metabolic acidosis in patients with low
glomerular filtration rate reduced the progression of kidney
disease. Fifty-nine patients with hypertensive nephropathy
and metabolic acidosis had their blood pressure reduced
with regimens that included angiotensin-converting enzyme
inhibition. Thirty patients were then prescribed sodium
citrate, and the remaining 29, unable or unwilling to
take sodium citrate, served as controls. All were followed
for 24 months with maintenance of their blood pressure
reduction. Urine endothelin-1 excretion, a surrogate
of kidney endothelin production, and N-acetyl-b-D-
glucosaminidase, a marker of kidney tubulointerstitial injury,
were each significantly lower, while the rate of estimated
glomerular filtration rate decline was significantly slower.
The estimated glomerular filtration rate was statistically
higher after 24 months of sodium citrate treatment
compared to the control group. Hence it appears that
sodium citrate is an effective kidney-protective adjunct
to blood pressure reduction and angiotensin-converting
enzyme inhibition.
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Subjects with low glomerular filtration rate (GFR) can have
metabolic acidosis1 and treatment guidelines recommend
alkali treatment for those with serum total CO2 (TCO2)
o22mM.2 Metabolic acidosis mediates GFR decline in the
five-sixths nephrectomy model of low GFR and its ameliora-
tion with oral alkali slows GFR decline in most3–5 but not all6
studies. Daily oral NaHCO3 administration for 2 years slowed
the decline rate of creatinine clearance in subjects with low
GFR for various causes7 but no mechanisms for this alkali
effect were reported. Metabolic acidosis-induced GFR decline
in the five-sixths nephrectomy model is mediated by
tubulointerstitial injury.3,5 In subjects with low GFR, 6 weeks
of daily oral NaHCO3 improved urine indices of kidney
tubule damage but did not improve GFR.8 Tubulointerstitial
injury is an important component of hypertensive nephro-
pathy,9 it might predict its progression,10 and many subjects
with hypertensive nephropathy experience progressive kidney
injury despite blood pressure (BP) reduction with regimens
that include angiotensin-converting enzyme (ACE) inhibi-
tion.11 Consequently, metabolic acidosis-induced tubuloin-
terstitial injury that is not ameliorated by conventional
kidney-protective strategies might contribute to kidney
injury in subjects with low GFR due to hypertensive
nephropathy. Furthermore, metabolic acidosis-induced tu-
bulointerstitial injury in the five-sixths nephrectomy model is
mediated through endothelin receptors5 and endothelins
also mediate progressive tubulointerstitial injury induced by
unilateral ureteral obstruction.12 Kidney endothelin-1 (ET-1)
production is increased in the five-sixths nephrectomy
model13,14 and oral alkali decreases this production.5 If
metabolic acidosis induces tubulointerstitial injury in human
hypertensive nephropathy, these animal studies support
exploring endothelin as a mediator. We tested the hypothesis
that oral alkali amelioration of metabolic acidosis reduces
kidney endothelin production, reduces urine parameters of
tubulointerstitial injury, and slows GFR decline in subjects
with low GFR due to hypertensive nephropathy.
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RESULTS
Table 1 shows the characteristics of each group at study entry.
There were no statistically significant differences in demo-
graphic data or systolic blood pressure (SBP), venous TCO2
(VTCO2), plasma creatinine (Pcr), plasma cystatin C (Pcys),
or estimated GFR (eGFR) using either Pcr (eGFRcr) or Pcys
(eGFRcys) at study entry between subjects who subsequently
received no Naþ citrate (No-NaCit) or Naþ citrate (NaCit)
for 24 months. The NaCit group had a higher proportion of
white subjects than the No-NaCit group (23 vs 14%) but this
difference was not statistically significant (P¼ 0.59).
Table 2 shows SBP, Pcr, Pcys, and eGFR at 6 and 30
months after study entry. At 6 months, all subjects had
undergone 6 months of pharmacologic SBP reduction but
none had received Na+ citrate. At 30 months, NaCit but not
the No-NaCit subjects had been prescribed 24 months of
Naþ citrate, 1meq/kg HCO3 equivalent daily in three
divided doses and SBP reduction was maintained. Entry
SBP between the NaCit and No-NaCit groups (Table 1) was
not statistically different (P¼ 0.611). All subjects received
ACE inhibition (Materials and Methods) and most received it
as enalapril because this was the recommended ACE inhibitor
on our formulary. There was no difference in the distribution
of non-ACE drugs or diuretics among subjects in the two
groups. Pharmacologic antihypertensive treatment from 0 to
6 months (Materials and Methods) decreased SBP signifi-
cantly (Po0.0001 for each group) to the 6-month values
shown in Table 2. The SBP levels were similar between 6 and
30 months for both groups. The increase in Pcr and decrease
in eGFRcr from months 6 to 30 within each group were
statistically significant but there was no statistically signifi-
cant difference in Pcr or eGFRcr at 6 or 30 months between
groups. Similarly, there was a statistically significant increase
in Pcys and a statistically significant decrease in eGFRcys
from 6 to 30 months within each group. In contrast to the
creatinine data, Pcys was statistically significantly lower and
eGFRcys was statistically significant higher at 30 months in
NaCit than No-NaCit.
Table 3 shows the months 6 and 30 values for additional
parameters in No-NaCit and NaCit groups. VTCO2 increased
significantly in NaCit and decreased significantly in No-
NaCit. By contrast, urine 8 h net acid excretion decreased
significantly in NaCit but remained fairly constant in No-
NaCit, reflecting ingestion of the prescribed alkali in NaCit.
Urine Naþ excretion (UNaV) remained similar in No-NaCit
but there was a statistically significant increase in NaCit,
reflecting the obligate Naþ intake with Naþ citrate.
Similarly, there was almost no change urine Kþ excretion
Table 1 | General demographic characteristics, SBP, Pcr, and
eGFR at study entry in subjects before they were not treated
(No-NaCit) or treated (NaCit) with Na+ citrate
No-NaCit (n=29) NaCit (n=30) P-value
Males (%) 48 47 0.891
Black/white/Hispanic (%) 55/14/31 53/23/23 0.591
Mean±s.d. Mean±s.d.
Age (years) 53.9±5.0 54.1±6.4 0.928
SBP (mmHg) 160.5±8.9 161.8±10.8 0.611
VTCO2 (mM) 20.6±0.8 20.8±1.2 0.375
Pcr (mg/dl) 3.20±0.89 3.27±0.70 0.733
eGFRcr (ml/min) 33.4±8.4 33.0±8.5 0.871
Pcys (mg/l) 3.86±1.09 3.88±0.79 0.936
eGFRcys (ml/min) 32.3±8.1 31.7±8.3 0.767
Abbreviations: eGFR, estimated glomerular filtration rate; N, number of subjects per
group; Pcr, plasma creatinine; Pcys, plasma cystatin C; SBP, systolic blood pressure;
VTCO2, venous serum total CO2.
Table 2 | SBP, Pcr, and eGFR before (0 months) and after 24 months of No-NaCit vs NaCit
No-NaCit (n=29) NaCit (n=30) P-value, NaCit vs No-NaCit
Month 6 Month 30
P-value,
30 vs 6 months Month 6 Month 30
P-value,
30 vs 6 months Month 6 Month 30
SBP 132.1±6.3 131.9±3.8 0.870 132.4±6.2 132.7±5.7 0.761 0.839 0.490
Pcr (mg/dl) 3.30±0.91 4.24±1.55 o0.0001 3.31±0.69 3.61±0.78 o0.0001 0.954 0.057
eGFRcr (ml/min) 32.5±8.3 24.9±9.7 o0.0001 32.7±8.2 29.5±8.8 o0.0001 0.945 0.066
Pcys (mg/l) 3.94±1.10 5.24±1.41 o0.0001 3.93±0.80 4.33±0.89 o0.0001 0.952 0.005
eGFRcys (ml/min) 31.7±7.9 23.0±6.05 o0.0001 31.4±8.2 27.8±7.4 o0.0001 0.885 0.008
Abbreviations: eGFR, estimated glomerular filtration rate; Pcr, plasma creatinine; Pcys, plasma cystatin; SBP, systolic blood pressure.
Table 3 | Changes in parameters after 24 months of No-NaCit vs NaCit (means±s.e.)
No-NaCit (n=29) NaCit (n=30) P-value, NaCit vs No-NaCit
Month 6 Month 30
P-value,
30 vs 6 months Month 6 Month 30
P-value,
30 vs 6 months Month 6 Month 30
VTCO2 (mM) 20.5±0.8 19.6±1.2 o0.0001 20.5±1.1 23.8±1.0 o0.0001 0.918 o0.0001
8 h Urine NAE (meq) 26.0±3.1 26.1±3.1 0.833 25.4±3.2 11.2±3.7 o0.0001 0.433 o0.0001
UNaV (meq/g Cr) 75.7±6.7 75.3±6.6 0.548 75.4±7.6 88.0±10.2 o0.0001 0.864 o0.0001
UKV (meq/g Cr) 36.4±5.3 36.4±4.5 0.950 37.6±5.7 39.7±5.9 0.0001 0.421 0.019
Plasma [Ca2+]ionized (mM) 1.12±0.06 1.13±0.06 0.370 1.13±0.05 1.09±0.05 o0.0001 0.592 0.005
Plasma PO4 (mg/dl) 3.98±0.38 4.09±0.42 0.085 4.11±0.31 4.15±0.31 0.239 0.166 0.510
Abbreviations: N, number of subjects in each group; NAE, net acid excretion; UKV, urine K
þ excretion; UNaV, urine Na
þ excretion; VTCO2, venous serum total CO2.
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(UKV) in No-NaCit but UKV increased significantly in NaCit.
Plasma ionized [Ca2þ ] decreased significantly in NaCit but
remained fairly constant in No-NaCit. The change in plasma
PO4 was not significant in either group. No subject met
Caþ þ /PO4 guidelines
15 to warrant PO4 binders or vitamin
D therapy.
Figure 1 shows that despite no statistically significant
differences (means±s.d.) in kidney endothelin production as
measured by urine ET-1 excretion (UET1V) between NaCit
and No-NaCit at study entry (5.97±2.31 vs 6.17±1.96 ng/g
Cr, respectively, P¼ 0.73) and at 6 months after SBP
reduction (6.06±1.97 vs 5.95±1.55 ng/g Cr, respectively,
P¼ 0.81), UET1V was statistically significantly lower in
NaCit than No-NaCit (4.83±1.47 vs 6.92±1.67 ng/g Cr,
respectively, Po0.0001) at month 30, that is, after 24 months
of Naþ citrate. Also, 30- vs 6-month values for UET1V
decreased significantly in NaCit (Po0.0001) but increased
significantly in No-NaCit (Po0.0001). Figure 2 shows that
despite no statistically significant differences in tubulointer-
stitial injury as measured by urine N-acetyl-b-D-glucosami-
nidase (NAG) excretion (UNAGV) between NaCit and No-
NaCit at study entry (9.32±3.53 vs 9.26±3.19U/g Cr,
respectively, P¼ 0.95) and at 6 months (8.93±2.92 vs
9.01±2.70U/g Cr, respectively, P¼ 0.92), UNAGV was
statistically significantly lower in NaCit than No-NaCit
(7.72±2.14 vs 10.37±3.15 ng/g Cr, respectively, P¼ 0.0004)
at month 30. Also, 30- vs 6-month values for UNAGV
decreased significantly in NaCit (Po0.004) yet increased
significantly in No-NaCit (Po0.0001). These data support
that kidney tubulointerstitial injury decreased with alkali
therapy but increased without it, following the same
directional pattern described for kidney ET-1 production.
Figures 3 and 4 show the course of change for the
remaining two urine indices of kidney injury. Figure 3 shows
that despite no statistically significant differences in urine
albumin excretion (UalbV) between NaCit and No-NaCit at
study entry (160.6±74.8 vs 145.6±54.7mg/g Cr, respec-
tively, P¼ 0.38) and at 6 months (132.0±66.3 vs
119.1±46.2mg/g Cr, respectively, P¼ 0.39), UalbV was
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Figure 1 |Box plots showing the course of urine endothelin-1
excretion (UET) as ng/g creatinine (ng per g Cr) in spot morning
specimens at study entry, after 6 months of blood pressure
(BP) reduction, and after an additional 24 months of daily
Naþ citrate (NaCit) or no Naþ citrate (No-NaCit) with
continuation of BP reduction, 30 months after study entry.
The dark line through each box indicates the median UET. The
box represents the inner quartile range of the differences in UET,
or the 25 and 75% percentiles of the UET differences. The lines
extending from the box indicate the range, or minimum and
maximum, of the differences in UET. Circles indicate values that
are considered outliers. *Po0.05 vs No-NaCit at the indicated time
point; þPo0.05 vs respective 6-month value within groups.
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Figure 2 |Box plots in the previously described format
showing the course of urine N-acetyl-b-D-glucosaminidase
(NAG) excretion (UNAGV) as U/g creatinine in spot morning
specimens at study entry, after 6 months of blood pressure
(BP) reduction, and after an additional 24 months of daily
Naþ citrate (NaCit) or no Naþ citrate (No-NaCit) with
continuation of BP reduction, 30 months after study entry.
*Po0.05 vs No-NaCit at the indicated time point; þPo0.05 vs
respective 6-month value within groups.
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Figure 3 |Box plots in the previously described format
showing the course of urine albumin excretion (UalbV) as
mg/g creatinine in spot morning specimens at study entry,
after 6 months of blood pressure (BP) reduction, and after
an additional 24 months of daily Naþ citrate (NaCit) or no
Naþ citrate (No-NaCit) with continuation of BP reduction,
30 months after study entry. *Po0.05 vs No-NaCit at the
indicated time point; þPo0.05 vs respective 6-month value
within groups.
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statistically significantly lower in NaCit than No-NaCit
(107.1±48.7 vs 146.9±44.6mg/g Cr, respectively, P¼ 0.002)
at month 30. Also, 30- vs 6-month values for UalbV decreased
significantly in NaCit (Po0.0001) but increased significantly
in No-NaCit (Po0.0001). In addition, entry compared to 6-
month UalbV was lower in both No-NaCit (Po0.0001) and
NaCit (Po0.0001) groups before either received alkali
therapy, likely reflecting the effects of SBP reduction. Figure 4
shows that despite no statistically significant differences in
urine transforming growth factor-b excretion (UTGFV)
between NaCit and No-NaCit at study entry (97.0±29.1 vs
99.1±32.1 ng/g Cr, respectively, P¼ 0.79) and at 6 months
(91.5±28.3 vs 96.6±29.1 ng/g Cr, respectively, P¼ 0.78),
UTGFV was statistically significantly lower in NaCit than No-
NaCit (80.8±30.1 vs 102.2±26.5 ng/g Cr, respectively,
P¼ 0.005) at month 30. Also, 30- vs 6-month UTGFV
decreased significantly in NaCit (Po0.003) but increased
significantly in No-NaCit (P¼ 0.004). Together, these data
support that kidney injury worsened with time in these
hypertensive nephropathy subjects with metabolic acidosis
but that daily Naþ citrate for 24 months decreased kidney
injury, possibly mediated through decreased kidney ET-1
production.
Comparisons using linear mixed models showed that
the yearly rate of eGFR decline was significantly slower in
NaCit than No-NaCit for eGFRcr (1.60±0.13 vs
3.79±0.30ml/min per year, Po0.0001) and eGFRcys
(1.82±0.08 vs 4.38±0.98ml/min per year, Po0.0001).
DISCUSSION
We tested the hypothesis that the recommended alkali
treatment of metabolic acidosis associated with low
GFR2 reduces kidney endothelin production, reduces urine
parameters of tubulointerstitial injury, and slows GFR decline
in subjects with low GFR due to hypertensive nephropathy.
Alkali prescribed as Naþ citrate was given after pharmaco-
logic SBP reduction because BP reduction was necessary to
show the ameliorating effects of alkali therapy on kidney
injury in the five-sixths model of low GFR.5 In addition, the
antihypertensive regimens of these hypertensive nephropathy
subjects with higher than normal UalbV included ACE
inhibition as recommended for hypertensive nephropathy
subjects with albuminuria16 and because of the suggestion
that ACE inhibition reduces hypertensive nephropathy
progression to chronic kidney disease (CKD) stage 5.17 The
data support that Naþ citrate reduces kidney ET-1 produc-
tion as measured by UET1V, reduces UNAGV, the marker of
kidney tubulointerstitial injury, and slows eGFR decline. By
contrast, subjects not prescribed Naþ citrate had increases in
UET1V and UNAGV as well as had faster eGFR decline,
supporting that this therapy also prevented what otherwise
would have been progressive kidney injury with faster eGFR
decline. This reduction in kidney injury and better eGFR
preservation was in addition to any provided by the
conventional kidney protection strategies of SBP reduction
and ACE inhibition. These studies suggest that treating
metabolic acidosis associated with low GFR due to
hypertensive nephropathy ameliorates progressive kidney
injury, some of which might be induced by endothelins,
and is an effective adjunct to SBP reduction and ACE
inhibition as a kidney protection strategy.
Earlier studies suggest mechanisms by which amelioration
of metabolic acidosis associated with low GFR reduces
UET1V. Kidney ET-1 production is increased by dietary acid
in animals with intact nephron mass18,19 and by metabolic
acidosis in animals with reduced nephron mass.5,13 This
increase includes higher kidney cortical interstitial ET-1 in
acid-ingesting animals with intact nephron mass18 and those
with reduced nephron mass and metabolic acidosis.14
Metabolic acidosis in subjects with low GFR might increase
kidney ET-1 through acid-induced ET-1 release from kidney
microvascular endothelium because an acid extracellular
environment within the physiologic range increases ET-1
release from human kidney microvascular endothelium in
vitro.20 ET-1 release from vascular endothelium is predomi-
nantly basolateral21 and so microvascular endothelium might
add ET-1 to cortical interstitium adjacent to the interstitial
space.22 Cortical epithelium secretes and releases basolateral
ET-123 and might also be a source of kidney cortical
interstitial ET-1.
The present studies specifically explored tubulointerstitial
injury as a mechanism for metabolic acidosis-induced kidney
injury because it is a consistent and important feature of
hypertensive nephropathy.9 The net increase in UNAGV in
No-NaCit and its net reduction in NaCit supports that
metabolic acidosis induces and its amelioration with Naþ
citrate reduces tubulointerstitial injury. Nevertheless, Naþ
citrate therapy was also associated with reduced UalbV and
reduced UTGFV and its absence was associated with increases
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Figure 4 |Box plots in the previously described format
showing the course of urine transforming growth factor-b1
excretion (UTGFV) as ng/g creatinine (ng/g Cr) in spot morning
specimens at study entry, after 6 months of blood pressure
(BP) reduction, and after an additional 24 months of daily
Naþ citrate (NaCit) or no Naþ citrate (No-NaCit) with
continuation of BP reduction, 30 months after study entry.
*Po0.05 vs No-NaCit at the indicated time point; þPo0.05 vs
respective 6-month value within groups.
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in each. Because tubulointerstitial injury contributes to UalbV
in some nephropathies,24 the suggested increase in tubu-
lointerstitial injury might contribute to the increase in UalbV.
Tubulointerstitial injury mediates GFR decline in five-sixths
nephrectomy3,5 and the present data support that Naþ
citrate reduces eGFR decline rate and leads to higher eGFRcys
after 24 months of therapy. Because eGFR calculations with
Pcys more accurately reflect GFR than those carried out with
Pcr,25 we consider that the statistically higher eGFRcys in
NaCit than No-NaCit supports better GFR preservation with
Naþ citrate, just as 2 years of NaHCO3 led to better
preservation of creatinine clearance in subjects with low GFR
for various causes.7
There are some limitations to be pointed out for this
study. The choice of treatment and not treatment with Naþ
citrate was not determined in a randomized manner for the
reasons stated in Materials and Methods. Nevertheless, the
two groups were very similar regarding entry characteristics
as detailed. In addition, the group numbers are small
although the indicated differences between them were highly
significant. It remains possible, however, that greater subject
numbers would yield different outcomes. This illustrates the
need for a larger-scale study to explore the efficacy of this
potentially effective and comparatively inexpensive adjunc-
tive kidney protection strategy.
In summary, these studies show that Naþ citrate, as
recommended for subjects with low GFR and VTCO2
o22mM, reduces kidney ET-1 production, reduces urine
parameters of kidney injury including tubulointerstitial
injury, and slows eGFR decline with better GFR preservation
in subjects with low GFR due to hypertensive nephropathy.
These studies support that Naþ citrate treatment of subjects
with low GFR due to hypertensive nephropathy be further
explored as an adjunctive kidney protection strategy to SBP
reduction and ACE inhibition.
MATERIALS AND METHODS
This prospective interventional study hypothesized that oral Naþ
citrate, 1meq of HCO3 equivalent/kg body weight per day in three
divided doses as recommended for subjects with low GFR and
VTCO2 o22mM,2 reduces kidney endothelin production and
tubulointerstitial injury in subjects with low GFR due to
hypertensive nephropathy. Primary outcome was urine ET-1
excretion (UET1V), a surrogate of kidney endothelin production
18
that mediates progressive kidney injury in experimental CKD
models.5,12,19 Secondary outcomes included urine excretion of
parameters of kidney injury and eGFR by MDRDS formula using
Pcr.26 Subsequent to protocol completion, cystatin C-derived eGFR
(eGFRcys) was calculated using the CKD-EPI equation.27 Urine
NAG excretion (UNAGV) was measured as a marker of kidney
tubulointerstitial injury,28 albumin excretion (UalbV) was measured
as a general marker of progressive kidney injury,29 and transforming
growth factor-b1 excretion (UTGFV) because it reflected kidney
injury induced by dietary acid in an experimental model of CKD5
and because it might be a mediator of hypertensive nephropathy.30
Urine net acid excretion was calculated by measuring urine titratable
acidity (TA), ammonium (NH4
þ ), and HCO3 ([NH4
þ ]þ [TA][HCO3]).
These parameters were followed in hypertensive nephropathy subjects
after lowering SBP toward recommended levels16 over 6 months and
maintaining the reduced SBP thereafter. Subjects with hypertensive
nephropathy, eGFR X20 but o60ml/min, and VTCO2 o22mM
were recommended Naþ citrate2 but some either refused it because
of its bad taste and/or because they could not afford it (it is not
covered by the local indigent health plan). Those who refused or
could not afford Naþ citrate were offered NaHCO3 tablets. Those
who accepted, could afford, and tolerated NaHCO3 were treated as
such but were not followed in this study. Those who did not tolerate
NaHCO3 (most commonly due to bloating), refused it and Na
þ
citrate outright, and agreed to participate in the study were enrolled
and followed as controls to the NaCit subjects and followed an
additional 24 months. They were instructed to take no over-the-
counter medications. Follow-up data were available for all recruited
subjects. Our local institutional review board approved the protocol.
The study sought subjects whose exclusive cause for low GFR was
hypertensive nephropathy. Candidates had been referred for control
of ‘resistant’ hypertension. Such referred subjects at our clinic
undergo duplex Doppler ultrasonography and serum aldosterone/
renin ratios to help rule out renal artery stenosis31 and hyper-
aldosteronism,32 as contributors to ‘resistant’ hypertension. Inclu-
sion criteria were (1) ageX18 years and able to give consent, (2)X2
visits with their primary care providers showing compliance with
clinic visits, and (3) 20p eGFRo60ml/min. Exclusion criteria were
(1) known primary kidney disease or findings consistent thereof
such asX3 red blood cells per high-powered field of urine or urine
cellular casts; (2) history of diabetes or fasting blood glucose
X110mg/dl; (3) history of malignances, chronic infections,
pregnancy, or clinical evidence of cardiovascular disease; (4)
peripheral edema or diagnoses associated with edema such as
heart/liver failure or nephrotic syndrome; (5) history of taking
Alþ þ -containing products; (6) and Doppler studies and/or serum
aldosterone/renin ratios consistent with renal artery stenosis and/or
primary hyperaldosteronism, respectively; or (7) history of medica-
tion noncompliance.
Improved BP control reduces the rate of GFR decline in subjects
with hypertensive nephropathy33 and guidelines recommend that
ACE inhibitors be included in the drug regimens of such subjects.16
Consequently, all subjects underwent a BP reduction protocol34
including ACE inhibition as tolerated for 6 months that was
maintained through 30 months. Those unable to tolerate ACE
inhibition were excluded. Subjects had visits at least every 6 months
with measurements of the indicated parameters and were followed
for 30 months.
Analytical methods
Serum and urine creatinine and urine albumin were measured using
the Sigma Diagnostics Creatinine Kit (Procedure No. 555; Sigma
Diagnostics, St Louis, MO, USA).35 Cystatin C was measured using a
particle-enhanced immunonephelometric assay (N Latex Cystatin C;
Dade Behring, Somerville, NJ) with a nephelometer (BNII; Dade
Bering).25,36 Urine ET-1 was measured using a RIA kit (Peninsula
Laboratories, Belmont, CA) after extraction using Bound Elut c/8
columns (Varian, Harbor City, CA, USA) preconditioned with methanol,
H2O, and acetic acid as carried out previously.
37 Urine TGF-b was
measured using quantitative sandwich enzyme immunoassay.38
Urine NAG was measured using a colorimetric assay (Boehringer
Mannheim, Mannheim, Germany).3 The IRMA SL Series 2000
blood analysis system (Edison, NJ) measured venous plasma/blood
pH, pCO2, and ionized calcium. This system calculated TCO2.
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Serum phosphate was measured with the Hitachi autoanalyzer
(Norcross, GA, USA). Urine TA was measured by correction to the
ambient serum pH by NaOH addition, NH4
þ by the formalin
titrimetric (to ambient serum pH) method,39 and urine HCO3 (as
TCO2) was measured by ultrafluorometry.
40 All urine parameters
were expressed per gram creatinine of a spot a.m. specimen.
Statistical methods
Patient characteristics at the time of study enrollment were tabulated
or described by mean and standard deviation (s.d.) as appropriate.
At this time point, categorical variables were compared between the
treatment and control group with the w2-test and continuous
measures were compared between the groups with the two-sample
t-test. Similarly, measurements of markers at baseline, 6, and
30 months for each group were plotted and described by mean and
s.d. The change from 6 to 30 months within each group was
considered with a one-sample t-test. The differences between the
two groups at each time point were considered with a two-sample
t-test. We considered whether the rate of change between 6 and 30
months was different between the two groups. We fit linear mixed
models with terms for treatment (NaCit vs No-NaCit), time (6 vs 30
months), and the interaction between the two. Linear mixed models
are used in situations in which data are correlated over more than
two time points, as with this study. An important choice in a linear
mixed model, which affects the validity of hypothesis tests, is the
error/correlation structure within each subject. For this study, the
measurements are not equally spaced in time and so the error/
correlation structure within each patient over time was modeled
using a general symmetric structure. Because ‘practical experience
based on many longitudinal studies has led to the empirical
observation that variances are rarely constant over time’,41 account
was also taken of the possibility that the variance changed over time.
We used restricted maximum likelihood estimation to fit each
model. Analyses were performed using R 2.4.1 (R Core Develop-
ment Team, 2006). All statistical tests were two sided and P-values
less than 0.05 were considered statistically significant. No adjust-
ments were made for multiple statistical tests.
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